Vitamine K epoxide reductase: fresh blood for oral anticoagulant therapies;La vitamine K époxyde réductase : du sang neuf dans les traitements anticoagulants oraux

Revue de Medecine Interne

Volumn 27, Issue 12, 2006, Pages 979-982

  Loriot, M A ^a,b   Beaune, P ^a,b  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Interpatient variability; Oral anticoagulants; VKORC1

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT I; VITAMIN K GROUP; WARFARIN;

AMINO ACID SUBSTITUTION; ANTICOAGULANT THERAPY; BLOOD; BLOOD CLOTTING; CARBOXYLATION; ENZYME INACTIVATION; GENETIC POLYMORPHISM; HAPLOTYPE; HOMOZYGOSITY; HUMAN; PHARMACOGENETICS; SHORT SURVEY;

ADMINISTRATION, ORAL; ALGORITHMS; ANTICOAGULANTS; DRUG RESISTANCE; HUMANS; MIXED FUNCTION OXYGENASES; MUTATION; POLYMORPHISM, GENETIC; VITAMIN K;

EID: 33750959627     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.09.004     Document Type: Short Survey

References (14)

1. Bell R.G. Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K-epoxide cycle. Fed. Proc. 37 (1978) 2599-2604
2. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.J., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004) 537-541
3. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
4. Tie J.K., Nicchitta C., von Heijne G., and Stafford D.W. Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. J. Biol. Chem. 280 (2005) 16410-16416
5. Wajih N., Hutson S.M., Owen J., and Wallin R. Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle. J. Biol. Chem. 280 (2005) 31603-31607
6. Linder M.W., and Valdes R. Genetic mechanisms for variability in drug response and toxicity. J. Anal. Toxicol. 25 (2001) 405-413
7. Pelz H.J., Rost S., Hunerberg M., Fregin A., Heiberg A.C., Baert K., et al. The genetic basis of resistance to anticoagulants in rodents. Genetics 170 (2005) 1839-1847
8. D'Andrea G., D'Ambrosio R.L., Di Perna P., Chetta M., Santacroce R., Brancaccio V., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2005) 645-649
9. Bodin L., Verstuyft C., Tregouet D.A., Robert A., Dubert L., Funck-Brentano C., et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106 (2005) 135-140
10. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352 (2005) 2285-2293
11. Montes R., Ruiz de Gaona E., Martinez-Gonzalez M.A., Alberca I., and Hermida J. The -1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br. J. Haematol. 133 (2006) 183-187
12. Aquilante C.L., Langaee T.Y., Lopez L.M., Yarandi H.N., Tromberg J.S., Mohuczy D., et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharm. Ther. 79 (2006) 291-302
13. Geisen C., Watzka M., Sittinger K., Steffens M., Daugela L., Seifried E., et al. VKORC1 haplotypes and their impact on the interindividual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94 (2005) 773-779
14. Sconce E.A., Khan T.I., Wynne H.A., Avery P., Monkhouse L., King B.P., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 (2005) 2329-2333